A Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea and its application

Abstract

The present invention discloses a Lactobacillus rhamnosus composition for alleviating gastrointestinal diarrhea and its application. The composition is composed of a probiotic mixture, a prebiotic mixture and a carrier. The probiotic mixture is composed of Lactobacillus plantarum JY055 powder, Lactobacillus rhamnosus JM039 powder and Lactobacillus rhamnosus JY027 powder. The prebiotic mixture includes inulin, xylitol, lactulose, resistant dextrin, hawthorn extract and dandelion extract. The carrier is modified montmorillonite. The composition for alleviating gastrointestinal diarrhea provided by the present invention is composed of three probiotics and a prebiotic mixture. The probiotics adhere to the small intestinal mucosal epithelial cells to form a biofilm, constituting an intestinal barrier to prevent the colonization and growth of harmful bacteria, enhance the self-protection of intestinal epithelial cells and repair the damaged intestinal barrier; while the prebiotic mixture provides a breeding place and nutrient elements for the growth and reproduction of probiotics, and the two cooperate with each other to improve the drug efficacy.

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical technology, and particularly relates to a Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea and its application. Background Art

[0002] There are a large number, wide variety and complex functions of microorganisms in the human intestine, and the number of its cells is more than 10 times that of human cells. Under normal conditions, the intestinal flora restricts and coordinates with each other, jointly maintaining a complex and stable intestinal microbial ecological balance; once this balance is broken, the intestinal flora is disordered, the number of probiotics decreases, the number of pathogenic bacteria increases, and various diseases related to the intestinal flora will follow. Diarrhea, as a common intestinal disease, is mainly clinically manifested by an increase in the amount of defecation, defecating 3 times or more a day, and abnormal fecal traits, such as loose stools and watery stools.

[0003] The main functions of the gastrointestinal system are to absorb and excrete fluids and nutrients. Its operation mechanism is complex. Under the influence of certain factors, the intestinal microecosystem is damaged, resulting in abnormal changes in the types, numbers and proportions of normal intestinal flora, showing a pathological combination state, thus causing diarrhea. Acute diarrhea remains a worldwide public health problem, especially in developing countries, and is an important cause of morbidity and death in children. The most common cause of diarrhea is infection by different microorganisms, and its most common complication is dehydration.

[0004] At present, the treatment of diarrhea mainly uses antibiotic drugs. However, frequent use of a large amount of antibiotics makes Escherichia coli resistant, destroys the normal flora in the intestine, and the residues of antibiotics also pose a great threat to daily production and life. Therefore, there is an urgent need for a drug that can relieve diarrhea without destroying the intestinal flora microecological balance to replace antibiotics. Summary of the Invention

[0005] The main object of the present invention is to propose a Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea and its application, aiming to solve the problem that the existing antibiotic drugs for treating diarrhea destroy the normal flora in the intestine.

[0006] To achieve the above object, the present invention proposes a Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea. The composition is composed of a probiotic mixture, a prebiotic mixture and a carrier. The probiotic mixture is composed of Lactobacillus plantarum JY055 powder, Lactobacillus rhamnosus JM039 powder and Lactobacillus rhamnosus JY027 powder. The prebiotic mixture includes inulin, xylitol, lactulose, resistant dextrin, hawthorn extract and dandelion extract. The carrier is modified montmorillonite.

[0007] The Lactobacillus plantarum JY055 provided by the present invention can produce exopolysaccharides, enhance the intestinal adhesion ability of Lactobacillus rhamnosus JM039 and Lactobacillus rhamnosus JY027. Lactobacillus rhamnosus JM039 helps to inhibit intestinal inflammatory responses, and Lactobacillus rhamnosus JY027 can improve colonic mucosal damage. The three probiotics cooperate with each other to improve the intestinal microbial balance. The modified montmorillonite provided by the present invention can bind to mucin glycoproteins, enhance the defense function of the intestinal mucosal barrier, thereby facilitating the restoration of the intestinal flora balance and inhibiting the body's inflammatory level. The modified montmorillonite has good dispersibility, provides a breeding place for the three probiotics of Lactobacillus plantarum JY055, Lactobacillus rhamnosus JM039 and Lactobacillus rhamnosus JY027, and is conducive to the colonization and growth of probiotics. The dandelion extract has pharmacological effects such as anti-inflammatory, anti-pathogenic bacteria, and antioxidant. The hawthorn extract is rich in flavonoids, polyphenols and organic acids, can promote the growth of Lactobacillus plantarum JY055, Lactobacillus rhamnosus JM039 and Lactobacillus rhamnosus JY027 in the intestine, and inhibit the proliferation of harmful flora, thereby enhancing the balance of the intestinal microecology. Lactulose reaches the colon and is decomposed by bacteria into lactic acid, stimulating intestinal peristalsis and playing a laxative role.

[0008] Optionally, the mass ratio of the probiotic mixture to the prebiotic mixture is (3-6):(4-8).

[0009] Optionally, the viable count of the Lactobacillus plantarum JY055 powder ≥ 1.0×10 9 CFU / g, the viable count of the Lactobacillus rhamnosus JM039 powder ≥ 1.0×10 8 CFU / g, the viable count of the Lactobacillus rhamnosus JY027 powder ≥ 2.0×10 8 CFU / g.

[0010] Optionally, the mass ratio of the Lactobacillus plantarum JY055 powder, Lactobacillus rhamnosus JM039 powder, and Lactobacillus rhamnosus JY027 powder in the probiotic mixture is (6-8):(4-5):(1-3).

[0011] Optionally, the preparation method of the modified montmorillonite includes the following steps:

[0012] Add an NaCl solution to montmorillonite, stir, centrifuge to remove the supernatant and wash with deionized water, dry, and crush to obtain Na-based montmorillonite; dissolve chitosan in acetic acid, add the Na-based montmorillonite, stir, centrifuge to remove the supernatant and wash with deionized water, dry, and crush to obtain modified montmorillonite.

[0013] Optionally, the mass ratio of inulin, xylitol, lactulose, resistant dextrin, hawthorn extract, dandelion extract, and modified montmorillonite is (1-2):(1-3):(2-5):(0.2-0.6):(6-10):(4-7):(0.2-0.4).

[0014] The present invention also provides a method for preparing the Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea as described above, comprising the following steps: stirring and mixing inulin, xylitol, lactulose, resistant dextrin, hawthorn extract, dandelion extract, and modified montmorillonite evenly in proportion, sterilizing at 110-130°C, and then adding Lactobacillus plantarum JY055 powder, Lactobacillus rhamnosus JM039 powder, and Lactobacillus rhamnosus JY027 powder, and mixing evenly to obtain the Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea.

[0015] The present invention also provides the application of the composition as described above in the preparation of drugs for relieving diarrhea.

[0016] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0017] (1) The Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea provided by the present invention is composed of a mixture of three probiotics and prebiotics. The probiotics adhere to the small intestinal mucosal epithelial cells to form a biofilm, constituting an intestinal barrier to prevent the colonization and growth of harmful bacteria, and enhancing the self-protection of intestinal epithelial cells and the repair of damaged intestinal barriers; while the prebiotic mixture provides a breeding place and nutrients for the growth and proliferation of probiotics, and the two cooperate with each other to improve the drug efficacy; the composition provided by the present invention can effectively regulate the intestinal microflora balance and relieve diarrhea through the reasonable combination and interaction of the components in the probiotic mixture and the prebiotic mixture. Description of the Drawings

[0018] In order to more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the following will briefly introduce the drawings required for the description of the embodiments or the prior art. Obviously, the following drawings are only some embodiments of the present invention. For those of ordinary skill in the art, other related drawings can be obtained based on these drawings without creative efforts.

[0019] Figure 1 It is a fecal character score chart for Embodiments 1-3 and Comparative Examples 1-5 of the present invention.

[0020] The realization, functional characteristics, and advantages of the object of the present invention will be further described with reference to the embodiments and the drawings. Detailed Embodiments

[0021] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be described clearly and completely below. For those not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. For reagents or instruments without indicating the manufacturer, they are all conventional products that can be obtained through commercial purchase. In addition, the technical solutions between various embodiments can be combined with each other, but it must be based on the fact that those skilled in the art can achieve it. When the combination of technical solutions is contradictory or cannot be achieved, it should be considered that such a combination of technical solutions does not exist and is not within the protection scope required by the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts belong to the protection scope of the present invention.

[0022] The technical solutions of the present invention will be further described in detail below in conjunction with specific embodiments and drawings. It should be understood that the following embodiments are only used to explain the present invention and are not used to limit the present invention.

[0023] Lactiplantibacillus plantarum JY055 was deposited with the Guangdong Provincial Microbial Culture Collection Center at the address of the 5th Floor of Building 59, No. 100, Xianlie Middle Road, Guangzhou City, Institute of Microbiology, Guangdong Academy of Sciences. The deposit date was August 27, 2022, and the deposit number was GDMCC.No62720. Lacticaseibacillus rhamnosus JM039 was deposited with the Guangdong Provincial Microbial Culture Collection Center on March 11, 2024, and the deposit number was GDMCC NO: 64409. Lacticaseibacillus rhamnosus JY027 was deposited with the Guangdong Provincial Microbial Culture Collection Center on November 21, 2022, and the deposit number was GDMCC NO: 62991. The hawthorn extract was purchased from Xi'an Minglang Biotechnology Co., Ltd.; the dandelion extract was purchased from Xi'an Jinheng Chemical Co., Ltd.

[0024] Preparation of Bacterial Powder

[0025] (1) Preparation of Lactiplantibacillus plantarum JY055 Bacterial Powder

[0026] Lactobacillus plantarum JY055 was inoculated into MRS liquid medium at an inoculation amount of 4%, and activated at 37 °C for 16 h. A small amount of the bacterial liquid was picked up with an inoculation loop and streaked on the MRS solid medium in three zones, cultured at 37 °C for 48 h, single colonies were picked and transferred to the fermentation medium, and cultured at 37 °C for 16 h to obtain bacterial cells. The bacterial cells were separated by centrifugation and added to a lyophilization protective solution containing 10% skim milk powder, 0.8% glutamic acid and 1% vitamin E. After mixing and freeze-drying, the Lactobacillus plantarum JY055 powder could be obtained. In this powder, the content of Lactobacillus plantarum JY055 was 1.2×10 9 cfu / g.

[0027] The MRS liquid medium, by mass fraction, includes: 2.0% glucose, 0.2% ammonium citrate, 0.5% sodium acetate, 0.03% manganese sulfate, 0.05% magnesium sulfate, 1.0% peptone, 1.0% beef extract, 0.5% yeast extract, 0.2% Tween-80, with the balance being water; pH 6.0 - 6.2.

[0028] The MRS solid medium, by mass fraction, includes: 2.0% glucose, 0.2% ammonium citrate, 0.5% sodium acetate, 0.03% manganese sulfate, 0.05% magnesium sulfate, 1.0% peptone, 1.0% beef extract, 0.5% yeast extract, 1.5% agar powder, 0.2% Tween-80, with the balance being water; pH 6.0 - 6.2.

[0029] (2) Preparation of Lactobacillus rhamnosus JM039 powder

[0030] Lactobacillus rhamnosus JM039 was inoculated into MRS liquid medium at an inoculation amount of 4%, and activated at 37 °C for 16 h. A small amount of the bacterial liquid was picked up with an inoculation loop and streaked on the MRS solid medium in three zones, cultured at 37 °C for 48 h, single colonies were picked and transferred to the fermentation medium, and cultured at 37 °C for 16 h to obtain bacterial cells. The bacterial cells were separated by centrifugation and added to a lyophilization protective solution containing 10% skim milk powder, 0.8% glutamic acid and 1% vitamin E. After mixing and freeze-drying, the Lactobacillus rhamnosus JM039 powder could be obtained. In this powder, the content of Lactobacillus rhamnosus JM039 was 1.5×10 8 cfu / g.

[0031] (3) Preparation of Lactobacillus rhamnosus JY027 powder

[0032] Lactobacillus rhamnosus JY027 was inoculated into MRS liquid medium at an inoculum size of 4%, and activated at 37 °C for 16 h. A small amount of the bacterial liquid was taken with an inoculation loop and streaked on MRS solid medium in three zones, and cultured at 37 °C for 48 h. Single colonies were picked and transferred to fermentation medium, and cultured at 37 °C for 16 h to obtain bacterial cells. The bacterial cells were separated by centrifugation, added to a freeze-drying protective solution containing 10% skim milk powder, 0.8% glutamic acid and 1% vitamin E, and freeze-dried after mixing to obtain Lactobacillus rhamnosus JY027 powder. In this powder, the content of Lactobacillus rhamnosus JY027 was 3.0×10 8 cfu / g.

[0033] The preparation of modified montmorillonite is as follows:

[0034] 100 mL of 1 mol / L NaCl solution was added to 10 g of montmorillonite, and magnetically stirred for 24 h. The supernatant was removed by centrifugation and washed with deionized water, and then dried at 60 °C for 24 h and crushed to obtain Na-based montmorillonite; 1 g of chitosan was dissolved in 50 mL of 5% acetic acid, and 10 g of Na-based montmorillonite was added, and stirred for 20 h. The supernatant was removed by centrifugation and washed with deionized water, and then dried for 24 h and crushed to obtain chitosan-modified montmorillonite.

[0035] Example 1

[0036] A preparation method of a Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea includes the following steps:

[0037] 1 part of inulin, 1 part of xylitol, 2 parts of lactulose, 0.2 part of resistant dextrin, 6 parts of hawthorn extract, 4 parts of dandelion extract and 0.2 part of modified montmorillonite were stirred and mixed evenly, sterilized at 120 °C, and then 6 parts of Lactobacillus plantarum JY055 powder, 4 parts of Lactobacillus rhamnosus JM039 powder and 1 part of Lactobacillus rhamnosus JY027 powder were added and mixed evenly to obtain the Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea.

[0038] Example 2

[0039] A preparation method of a Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea includes the following steps:

[0040] 2 parts of inulin, 3 parts of xylitol, 5 parts of lactulose, 0.6 part of resistant dextrin, 10 parts of hawthorn extract, 7 parts of dandelion extract and 0.4 part of modified montmorillonite were stirred and mixed evenly, sterilized at 120 °C, and then 8 parts of Lactobacillus plantarum JY055 powder, 5 parts of Lactobacillus rhamnosus JM039 powder and 3 parts of Lactobacillus rhamnosus JY027 powder were added and mixed evenly to obtain the Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea.

[0041] Example 3

[0042] A preparation method of a Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea, comprising the following steps:

[0043] Mix 1.5 parts of inulin, 2 parts of xylitol, 4 parts of lactulose, 0.4 part of resistant dextrin, 8 parts of hawthorn extract, 5 parts of dandelion extract and 0.3 part of modified montmorillonite evenly, sterilize at 120 °C, and then add 7 parts of Lactobacillus plantarum JY055 powder, 4.5 parts of Lactobacillus rhamnosus JM039 powder and 2 parts of Lactobacillus rhamnosus JY027 powder, mix evenly to obtain the Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea.

[0044] Comparative Example 1

[0045] A preparation method of a composition, comprising the following steps:

[0046] Mix 1 part of inulin, 1 part of xylitol, 2 parts of lactulose, 0.2 part of resistant dextrin, 6 parts of hawthorn extract, 4 parts of dandelion extract and 0.2 part of modified montmorillonite evenly, sterilize at 120 °C, and then add 4 parts of Lactobacillus rhamnosus JM039 powder and 1 part of Lactobacillus rhamnosus JY027 powder, mix evenly to obtain the composition.

[0047] Comparative Example 2

[0048] A preparation method of a composition, comprising the following steps:

[0049] Mix 1 part of inulin, 1 part of xylitol, 2 parts of lactulose, 0.2 part of resistant dextrin, 6 parts of hawthorn extract, 4 parts of dandelion extract and 0.2 part of modified montmorillonite evenly, sterilize at 120 °C, and then add 6 parts of Lactobacillus plantarum JY055 powder and 1 part of Lactobacillus rhamnosus JY027 powder, mix evenly to obtain the composition.

[0050] Comparative Example 3

[0051] A preparation method of a composition, comprising the following steps:

[0052] Mix 1 part of inulin, 1 part of xylitol, 2 parts of lactulose, 0.2 part of resistant dextrin, 6 parts of hawthorn extract, 4 parts of dandelion extract and 0.2 part of modified montmorillonite evenly, sterilize at 120 °C, and then add 6 parts of Lactobacillus plantarum JY055 powder and 4 parts of Lactobacillus rhamnosus JM039 powder, mix evenly to obtain the composition.

[0053] Comparative Example 4

[0054] A preparation method of a composition, comprising the following steps: [[ID=3,9]]

[0055] Mix 1 part of inulin, 1 part of xylitol, 2 parts of lactulose, 0.2 part of resistant dextrin, 6 parts of hawthorn extract, and 4 parts of dandelion extract evenly, sterilize at 120 °C, then add 6 parts of Lactobacillus plantarum JY055 powder, 4 parts of Lactobacillus rhamnosus JM039 powder, and 1 part of Lactobacillus rhamnosus JY027 powder, and mix evenly to obtain the composition.

[0056] Control Example 5

[0057] A method for preparing a composition, comprising the following steps:

[0058] Mix 1 part of inulin, 1 part of xylitol, 2 parts of lactulose, 0.2 part of resistant dextrin, 4 parts of dandelion extract, and 0.2 part of modified montmorillonite evenly, sterilize at 120 °C, then add 6 parts of Lactobacillus plantarum JY055 powder, 4 parts of Lactobacillus rhamnosus JM039 powder, and 1 part of Lactobacillus rhamnosus JY027 powder, and mix evenly to obtain the composition.

[0059] Testing methods and results

[0060] Method for establishing a mouse diarrhea model:

[0061] Select 6-8-week-old BALB / c mice. First, conduct adaptive feeding for one week, and then orally administer ETEC toxin (recorded as 1 mg / kg body weight) daily in addition to normal feed and water for 21 days. Continuously observe the diarrhea symptoms of the mice for at least 24 hours or more, and the successful establishment of the model is achieved.

[0062] Experimental grouping and dosing doses:

[0063] Randomly divide 45 successfully modeled 6-8-week-old BALB / c mice into 9 groups, with 5 mice in each group (diarrhea mice), and administer the compositions prepared in Examples 1 to 3 and Control Examples 1 to 5 respectively; the positive control group (5 diarrhea mice) takes Daqing antidiarrheal oral liquid; the negative control group (5 healthy mice) takes the same volume of distilled water. Administer orally once in the morning and once in the evening every day (recorded as 200 mg / kg body weight) for 30 days. The sampling time is 1 day before taking the composition and the 2nd day after the completion of taking the composition.

[0064] (1) Improvement effect of the composition on the diarrhea symptoms of diarrhea patients

[0065] Daily bowel movement frequency: During the intervention with the composition, the number of daily bowel movements in each group was counted weekly for all test mice. The average daily bowel movement frequency for each group was calculated. The bowel movement frequency of mice during the 4-week intervention with the composition is shown in Table 1. The obtained data were statistically processed and expressed as mean ± standard deviation (x ± s). The significance of the difference was determined by t-test. The P value was calculated by comparing the positive control group with the negative control group and comparing each drug-treated group with the positive control group. (** indicates a very significant difference with P < 0.01, and * indicates a significant difference with P < 0.05).

[0066] Table 1 Changes in patients' bowel movement frequency during the intervention period of the composition

[0067]

[0068]

[0069] As can be seen from Table 1, the average daily bowel movement frequency of the diarrheal mice was 35.9-39.7 times / day before the intervention of the composition, 32.6-32.8 times / day after 1 week of intervention with the composition of Examples 1-3 of the present invention, 27.3-29.5 times / day after 2 weeks of intervention with the composition, 21.0-25.9 times / day after 3 weeks of intervention with the composition, and 16.9-19.0 times / day after 4 weeks of intervention with the composition. The bowel movement frequency of the diarrheal mice in the embodiment group basically returned to normal levels; the bowel movement frequency of the diarrheal mice in the comparative examples 1-5 was 32.0-34.3 times / day after 1 week of intervention with the composition, 29.0-30.4 times / day after 2 weeks of intervention with the composition, 26.0-28.9 times / day after 3 weeks of intervention with the composition, and 22.5-24.7 times / day after 4 weeks of intervention with the composition. The bowel movement frequency of the diarrheal mice in the comparative example group did not return to normal levels.

[0070] Fecal trait score: During the intervention of the composition, the fecal trait score of all diarrhea mice was statistically analyzed for each group every week, and the daily average fecal trait score of each group was plotted. The fecal trait score of diarrhea mice within 4 weeks of the composition intervention was shown in Figure 2. Figure 1 .

[0071] Defecation 20 times or more per day, and abnormal stool characteristics, such as loose stools and watery stools. The stool characteristics are judged by the loose stool grade score. During the experiment, the stool shape of each group of mice was observed and the loose stool score was performed. Loose stool grade: As = normal stool 2 points, Bs = semi-solid stool 5 points, Cs = watery stool 8 points. The loose stool score of each group is the average of the loose stool scores of each breed of mice. The loose stool score of each mouse = (As x N1 + Bs x N2 + Cs x N3) / N, where As, Bs, and Cs are loose stool grade scores, N1, N2, and N3 are the number of times the corresponding loose stool grade occurs, and N is the total number of bowel movements.

[0072] As can be seen from Figure 1 that the average fecal character score of the diarrhea mice was 6.3 - 6.8 before the intervention of the composition, indicating obvious diarrhea symptoms; after taking the composition provided by the present invention for 1 week, the average fecal character score was 5.4 - 5.8, and there were still diarrhea symptoms, but the symptoms were alleviated; after taking it for 2 weeks, the average fecal character score was 4.7 - 4.9, basically reaching the normal level; after taking it for 3 weeks, the average fecal character score was 4.0 - 4.3, and after taking it for 4 weeks, the average fecal character score was 4.0 - 4.2, achieving an ideal fecal form. After taking the composition provided by the comparative example for 1 week, the average fecal character score was 6 - 6.5, and there were still diarrhea symptoms, but the symptoms were alleviated; after taking it for 2 weeks, the average fecal character score was 5.8 - 6.4, and there were still diarrhea symptoms; after taking it for 3 weeks, the average fecal character score was 5.7 - 6.1, and after taking it for 4 weeks, the average fecal character score was 5.2 - 6.0, and there was still diarrhea.

[0073] (2) Influence of the composition on intestinal flora

[0074] Before and 2 hours after the test, feces of healthy mice were aseptically collected, and the fecal intestinal flora was detected using a 16S rRNA intestinal gene detection kit. The gene expression levels of Bacteroides, Prevotella, and Staphylococcus aureus in the feces were counted, and the average value of each group was calculated. The results are shown in Table 2.

[0075] Table 2 Statistical table of the influence of the composition on intestinal flora

[0076]

[0077] As can be seen from Table 2, for the mice taking the composition of the present invention, the contents of Bacteroides and Prevotella in the intestine increased compared with before taking, and at the same time, the content of Staphylococcus aureus decreased compared with before taking. It shows that the composition of the present invention can regulate the intestinal flora and at the same time reduce the risk of diarrhea.

[0078] The above are only the preferred embodiments of the present invention, and do not limit the patent scope of the present invention. For those skilled in the art, the present invention can have various changes and modifications. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included within the patent protection scope of the present invention.

Claims

1. A Lactobacillus rhamnosus composition for alleviating gastrointestinal diarrhea, characterized in that: The composition consists of a probiotic mixture, a prebiotic mixture and a carrier, wherein the probiotic mixture consists of Lactobacillus plantarum JY055 powder, Lactobacillus rhamnosus JM039 powder and Lactobacillus rhamnosus JY027 powder, the prebiotic mixture includes inulin, xylitol, lactulose, resistant dextrin, hawthorn extract and dandelion extract, and the carrier is modified montmorillonite; The preparation method of the modified montmorillonite comprises the following steps: NaCl solution is added to montmorillonite, stirred, centrifuged to remove the supernatant, washed with deionized water, dried, and crushed to obtain Na-based montmorillonite; chitosan is dissolved in acetic acid, and the Na-based montmorillonite is added, stirred, centrifuged to remove the supernatant, washed with deionized water, dried, and crushed to obtain modified montmorillonite; The mass ratio of the probiotic mixture and the prebiotic mixture is (3-6): (4-8); the mass ratio of Lactobacillus plantarum JY055 powder, Lactobacillus rhamnosus JM039 powder, and Lactobacillus rhamnosus JY027 powder in the probiotic mixture is (6-8): (4-5): (1-3); the mass ratio of inulin, xylitol, lactulose, resistant dextrin, hawthorn extract, dandelion extract, and modified montmorillonite is (1-2): (1-3): (2-5): (0.2-0.6): (6-10): (4-7), (0.2-0.4).

2. The Lactobacillus rhamnosus composition for alleviating gastrointestinal diarrhea according to claim 1, wherein The viable bacterial count of the Lactobacillus plantarum JY055 powder is ≥1.0×10 9 CFU / g, the viable count of the Lactobacillus rhamnosus JM039 powder is ≥1.0×10 8 CFU / g, the viable count of the Lactobacillus rhamnosus JY027 powder is ≥2.0×10 8 CFU / g.

3. A method for preparing a Lactobacillus rhamnosus composition for alleviating gastrointestinal diarrhea according to any one of claims 1 to 2, characterized in that: The following steps are involved: Inulin, xylitol, lactulose, resistant dextrin, hawthorn extract, dandelion extract and modified montmorillonite are stirred and mixed uniformly in proportion, sterilized at 110-130°C, and then Lactobacillus plantarum JY055 powder, Lactobacillus rhamnosus JM039 powder and Lactobacillus rhamnosus JY027 powder are added and mixed uniformly to obtain a Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea.

4. Use of the composition according to any one of claims 1 to 2 in the preparation of a drug for alleviating diarrhea.

Images